We are pleased to share with you that our partner, Hua Medicine, has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its novel 4th-Generation glucokinase activator (GKA) to treat Type 2 diabetes (T2DM). Hua Medicine is a leading, innovative drug development company in China focused on novel therapies for the treatment of diabetes and CNS disorders.  The company had earlier announced outstanding positive results from a multicenter Phase 1b trial in China. HMS5552 (also known as sinogliatin) demonstrated excellent 24-hour glucose control of both fasting and post-meal glucose, robust
glucose-dependent insulin release, and very low risk of hypoglycemia throughout the trial in Chinese T2DM patients.  The company will start long-term Phase 2 trials in China in the 2Q2015, while concurrently starting the Phase 1 metformin-GKA combination studies in the US.

 

Related Links:

Official press release
Hua Medicine Breaking New Ground